Sistema de Salut de Catalunya
Institut Català de la Salut
[Brochet B] INSERM U 1215, University of Bordeaux, Bordeaux, France. [Solari A] Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. [Lechner-Scott J] University of Newcastle, Newcastle, NSW, Australia. Division of Neurology, John Hunter Hospital, Newcastle, NSW, Australia. [Piehl F] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. [Langdon D] Department of Psychology, Royal Holloway, University of London, Egham, UK. [Hupperts R] Zuyderland Medisch Centrum Sittard, Maastricht University Medical Center, Maastricht, The Netherlands. [Montalban N] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-01-15T08:10:21Z
2025-01-15T08:10:21Z
2024
Quality of life; Relapsing multiple sclerosis; Tablets
Calidad de vida; Esclerosis múltiple recurrente; Comprimidos
Qualitat de vida; Esclerosi múltiple recurrent; Comprimits
What is this summary about? This article summarises the findings from the CLARIFY-MS study. Cladribine tablets are an oral medication for the treatment of relapsing multiple sclerosis (MS). The exact number of tablets and number of days depends on the person's body weight. In the CLARIFY-MS study, researchers investigated whether treatment with cladribine tablets improved the health-related quality of life of people with highly active relapsing MS over a 2-year period. Most of the participants(348/482, 72%) were previously treated with other MS diseasemodifying treatments(DMTs) before starting treatment with cladribine tablets in this study. What were the results? Treatment with cladribine tablets significantly improved the health-related quality of life of the participants over the 2-year study period. Similar level of improvement in health-related quality of life was seen in participants who had previously been treated with other MS DMTs and in those who had not. Safety findings were also similar to previously reported data for cladribine tablets. No cases of the most severe grade of reduction in lymphocyte counts (grade 4; severely compromised immune system) were recorded. What do the results mean? Treatment with cladribine tablets improves the health-related quality of life of people with highly active relapsing MS regardless of whether they received or did not receive DMTs for MS before cladribine tablets treatment.
The CLARIFY-MS study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945).
Article
Versió publicada
Anglès
Pacients - Satisfacció; Esclerosi múltiple - Tractament; Medicaments antineoplàstics - Ús terapèutic; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting; Other subheadings::Other subheadings::Other subheadings::/drug therapy; HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos; Otros calificadores::Otros calificadores::/uso terapéutico
Taylor & Francis
Neurodegenerative Disease Management;14(6)
https://doi.org/10.1080/17582024.2024.2429970
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - CEMCAT [136]
Articles científics - HVH [3396]
